Study guide
7.1 Viral Infections (HIV, EBV, Influenza)
NCCPA PANCE Physician Assistant Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular System
1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)
2 Chapter 2: Pulmonary System
Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions
3 Chapter 3: Gastrointestinal/Nutrition
3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies
4 Chapter 4: Musculoskeletal System
Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)
5 Chapter 5: Neurologic System
Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders
6 Chapter 6: Psychiatry/Behavioral Science
Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders
7 Chapter 7: Infectious Diseases
7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)
8 Chapter 8: Reproductive System
8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections
9 Chapter 9: Endocrine System
Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders
10 Chapter 10: Eyes, Ears, Nose, and Throat
Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)
11 Chapter 11: Professional Practice
11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines
12 Chapter 12: Hematologic System
Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
13 Chapter 13: Renal System
13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases
14 Chapter 14: Dermatologic System
Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management
15 Chapter 15: Genitourinary System
Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma
7.1 Viral Infections (HIV, EBV, Influenza)
Key Takeaways Explain This Topic AI
HIV/AIDS is defined by a CD4 count < 200 cells/uL or an AIDS-defining illness (key thresholds include < 200 for PCP and < 100 for Toxoplasmosis); primary prophylaxis for MAC (< 50) is no longer routinely recommended if starting ART immediately.
Abacavir requires HLA-B*5701 testing prior to administration to prevent a potentially fatal systemic hypersensitivity reaction.
Infectious mononucleosis is caused by EBV (HHV-4), presents with posterior cervical lymphadenopathy, fever, and pharyngeal exudate, and requires avoiding contact sports for at least 3-4 weeks to prevent splenic rupture.
Amoxicillin or ampicillin administration in a patient with active EBV mononucleosis causes a classic, non-allergic maculopapular rash.
Influenza neuraminidase inhibitors (Oseltamivir) are most effective within 48 hours of symptom onset but should be given regardless of timing in high-risk patients (elderly, pregnant, chronic disease).
Last updated: July 2026
- 7.1 Viral Infections (HIV, EBV, Influenza)
- Why This Matters for the PANCE
Viral infections are a high-yield component of the PANCE blueprint, representing common acute and chronic pathologies in primary care and emergency departments. Candidates must master:
HIV stages, diagnostic algorithm, CD4 thresholds, and prophylactic regimens for major opportunistic infections (PCP, Toxoplasmosis, and MAC).
Epstein-Barr Virus (EBV) clinical presentation, atypical lymphocytes, splenic rupture, and contact sports restrictions.
Influenza pathophysiology (drift vs. shift), diagnostic testing, and the clinical indications and timing of neuraminidase inhibitors.
- HIV & AIDS
- Pathophysiology & Stages
HIV is an enveloped retrovirus that infects CD4+ helper T cells, macrophages, and dendritic cells. The envelope glycoprotein gp120 binds to the host CD4 receptor and a co-receptor (CCR5 or CXCR4), while gp41 facilitates membrane fusion. Once inside, reverse transcriptase converts viral RNA into DNA, which integrase integrates into the host genome, leading to progressive CD4+ cell destruction.
Acute HIV Infection: Occurs 2–4 weeks post-exposure. Presents as a mononucleosis-like illness with fever, generalized lymphadenopathy, sore throat, maculopapular rash, and myalgias. Viral replication is extremely high.
Chronic HIV Infection: Often asymptomatic clinical latency lasting years.
AIDS: Defined by a CD4 count < 200 cells/uL OR the presence of an AIDS-defining condition (e.g., esophageal candidiasis, PCP, Kaposi sarcoma, cryptococcal meningitis).
Opportunistic Infection (OI) CD4 Thresholds
Prophylaxis is initiated based on CD4 count thresholds to prevent opportunistic infections:
CD4 count Pathogen Clinical Presentation Prophylaxis choice Alternative
< 200 cells/uL Pneumocystis jirovecii (PCP) Progressive dyspnea, dry cough, fever, hypoxia. Chest X-ray: bilateral interstitial infiltrates ("bat-wing" pattern). TMP-SMX DS 1 tablet PO daily Dapsone OR Atovaquone
< 100 cells/uL Toxoplasma gondii Headache, focal deficits, seizures. Brain MRI: multiple ring-enhancing lesions. TMP-SMX DS daily (if IgG positive) Dapsone + Pyrimethamine + Leucovorin
< 50 cells/uL Mycobacterium avium complex (MAC) High fever, night sweats, weight loss, abdominal pain, diarrhea, anemia. Azithromycin 1,200 mg PO weekly (see Update below) Clarithromycin
Important
Modern Guideline Update: Primary prophylaxis for MAC is no longer routinely recommended if the patient immediately initiates Antiretroviral Therapy (ART), as rapid CD4 recovery effectively minimizes MAC risk.
Diagnostics & Management
Screening: HIV-1/2 antigen/antibody combination immunoassay (detects HIV-1/2 antibodies and p24 antigen).
Confirmatory Testing: HIV-1/2 antibody differentiation immunoassay if screening is reactive.
Viral Load: HIV-1 RNA nucleic acid test (NAT) if the differentiation assay is indeterminate, detecting acute infection.
ART Principles: Initiated immediately upon diagnosis. First-line is a 3-drug regimen : 2 NRTIs (e.g., Tenofovir/Emtricitabine) PLUS 1 INSTI (e.g., Dolutegravir or Bictegravir).
PANCE Pearls: Screen for the HLA-B*5701 allele prior to starting Abacavir due to the risk of a fatal systemic hypersensitivity reaction. Tenofovir Disoproxil Fumarate (TDF) is linked to nephrotoxicity and osteopenia; Tenofovir Alafenamide (TAF) is a safer alternative.
- Epstein-Barr Virus (EBV) & Infectious Mononucleosis
- Clinical Presentation & Diagnostics
EBV is a Herpesvirus (HHV-4) transmitted via saliva. It infects B lymphocytes by binding to the CD21 receptor. Cytotoxic CD8+ T cells respond to control the infection, presenting as atypical lymphocytes. The classic clinical triad includes fever, tonsillar pharyngitis (severe, with thick white exudates), and posterior cervical lymphadenopathy (symmetric, tender). Splenomegaly (50%) and fatigue are common.
Diagnostics:
Smear: Atypical lymphocytes (Downey cells) , which are reactive CD8+ T cells with indented cytoplasm.
Heterophile Antibody Test (Monospot): Agglutination assay. Specific, but can be negative in the first week or in children < 4.
Serology: IgM anti-VCA (acute) and IgG anti-EBNA (past infection).
Clinical Management & PANCE Pearls
Splenic Rupture Risk: Patients must avoid contact sports, strenuous exercise, and heavy lifting for a minimum of 3 to 4 weeks from symptom onset. Spleen size should be clinically normal before clearance.
Amoxicillin Rash: Treating mono patients with amoxicillin or ampicillin causes a classic, non-allergic, maculopapular rash . This does not indicate a true penicillin allergy.
- Influenza
- Pathophysiology & Presentation
Influenza is a single-stranded RNA virus transmitted via respiratory droplets. Surface glycoproteins Hemagglutinin (HA) mediates viral entry, and Neuraminidase (NA) facilitates release.
Antigenic Drift: Minor point mutations in HA/NA causing seasonal epidemics (occurs in Influenza A and B).
Antigenic Shift: Major genetic reassortment creating completely new HA/NA proteins, leading to global pandemics (occurs only in Influenza A).
Symptoms: Abrupt onset of high fever, myalgias, headache, non-productive cough, sore throat, and fatigue.
Diagnostics & Management
Testing: Rapid Antigen Tests (RIDTs) have high specificity but moderate sensitivity (50-70%; a negative test does not rule out flu). RT-PCR is the gold standard.
Pharmacotherapy: Neuraminidase inhibitors like Oseltamivir (Tamiflu) block viral release. Most effective when started within 48 hours of symptom onset (reduces duration by 1–1.5 days). Initiate after 48 hours only if the patient is hospitalized, has progressive illness, or is at high risk (adults ≥ 65, children < 2, pregnancy, or chronic cardiorespiratory/metabolic disease).
Secondary Bacterial Pneumonia: Suspect if a patient improves and then suddenly deteriorates with high fever, productive cough, and dyspnea (commonly S. pneumoniae or S. aureus including MRSA).